Related Experiment Video
Updated: Jul 20, 2026

Brain Morphology of Cannabis Users With or Without Psychosis: A Pilot MRI Study
Published on: August 18, 2020
The prevalence of psychotic symptoms among methamphetamine users
Rebecca McKetin1, Jennifer McLaren, Dan I Lubman
1National Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW, Australia. r.mcketin@unsw.edu.au
Aims:
To examine the prevalence of psychotic symptoms among regular methamphetamine users.
Design:
Cross-sectional survey.
Setting:
Participants were recruited from Sydney, Australia, through advertisements in free-press magazines, flyers and through word-of-mouth.
Participants:
Methamphetamine users (n = 309) who were aged 16 years or over and took the drug at least monthly during the past year.
Measurements:
A structured face-to-face interview was used to assess drug use, demographics and symptoms of psychosis in the past year. Measures of psychosis included: (a) a psychosis screening instrument derived from the Composite International Diagnostic Interview; and (b) the Brief Psychiatric Rating Scale subscales of suspiciousness, unusual thought content, and hallucinations. Dependence on methamphetamine was measured using the Severity of Dependence Scale.
Findings:
Thirteen per cent of participants screened positive for psychosis, and 23% had experienced a clinically significant symptom of suspiciousness, unusual thought content or hallucinations in the past year. Dependent methamphetamine users were three times more likely to have experienced psychotic symptoms than their non-dependent counterparts, even after adjusting for history of schizophrenia and other psychotic disorders.
Conclusion:
The prevalence of psychosis among the current sample of methamphetamine users was 11 times higher than among the general population in Australia. Dependent methamphetamine users are a particularly high-risk group for psychosis.
More Related Videos
Related Concept Videos
Psychosis and Antipsychotic Drugs: Overview
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within the...
Psychosis: Goals of Pharmacotherapy
Psychological and Sociocultural Causes of Schizophrenia
Drug Abuse and Addiction: Pharmacological Phenomena
Positive Symptoms Schizophrenia: Hallucinations and Delusions
Hallucinations
Hallucinations in...

